These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3412024)

  • 1. A study on the induction of differentiation of human leukemic cells by harringtonine combined with cytarabine.
    Huang CL; Deng ML; Guo RJ; Wu MT; Liu FZ; Liang YM; Qiao QD
    Leukemia; 1988 Aug; 2(8):518-22. PubMed ID: 3412024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Differentiation induction of myeloid leukemia cells by glucocorticoid--the differentiation induction effect in vitro and in vivo].
    Nakamaki T; Sakashita A; Sano M; Hino K; Suzuki K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1989 Feb; 30(2):149-57. PubMed ID: 2746870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of differentiation of fresh human leukemic cells by low dose cytosine arabinoside (LD Ara-C) and 12-O-tetradecanoylphorbol-13-acetate (TPA).
    Kuliczkowski K; Noworolska A; Frydecka I; Sedek K; Harłozińska A
    Neoplasma; 1989; 36(5):589-97. PubMed ID: 2812152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
    Gustavsson A; Olofsson T
    Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W; Nowak B; Keating MJ
    Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic results of DCMP therapy (2M-80) in acute non-lymphocytic leukemia--the relationship between the residual leukemic cells and duration of remission].
    Moriyama Y; Urushiyama M; Ohnishi M; Koyama S; Hirosawa H; Hanano M; Fuse I; Takai K; Nagayama R; Fujiwara M; Kishi K; Takahashi M; Koike T; Sakai C; Kashimura M; Miura R; Aoyagi A; Sanada M; Hattori A; Shibata A; Shinada S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1549-54. PubMed ID: 6892201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
    Koyama S; Itou S; Shibata A
    Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
    Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system (CNS) leukemia: the role of high dose cytarabine (HDAra-C).
    Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Regazzi Bonora M; Pagnucco G; Orlandi E; Bernasconi P; Canevari A; Rondanelli R
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():101-3. PubMed ID: 2713552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination treatment of acute non-lymphocytic leukemia with HOAP and AA--preliminary report of 14 cases].
    Zhang GZ
    Zhonghua Zhong Liu Za Zhi; 1991 Jan; 13(1):52-4. PubMed ID: 1889339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
    Tafuri A; De Felice L; Petrucci MT; Mascolo MG; Ricciardi MR; Ciliberti C; Martelli MP; Petti MC
    Cytokines Mol Ther; 1995 Dec; 1(4):301-7. PubMed ID: 9384683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.